<DOC>
	<DOCNO>NCT00613496</DOCNO>
	<brief_summary>Experimental data suggest angiotensin II-antagonists reduce atrial expression prothrombotic adhesion molecule oxidative stress parameter . The present study design investigate effect angiotensin II-antagonist irbesartan reduce amount circulate oxidative stress marker adhesion molecule patient persistent atrial fibrillation .</brief_summary>
	<brief_title>Irbesartan Adhesion Molecules AF</brief_title>
	<detailed_description>Primary Objective : The aim study ass block angiotensin II type 1 receptor reduces systemic level oxidative stress marker adhesion molecule 25 % compare placebo patient persistent/permanent atrial fibrillation . Primary Target Parameter : The primary target parameter define reduction systemic level oxidative stress marker adhesion molecule ( hsCRP , ICAM , VCAM , MCP-1 , vWF , TGFβ1 , TNF-α , Interleukin-6 , 8isoProstaglandinF2α ) Secondary Target Parameter : The secondary Target Parameters define number cerebrovascular event , number intermediate medical visit cardiovascular reason without hospitalisation , number hospitalisation cardiovascular reason GFR .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Patients persistent/permanent AF ( &gt; 2 month ) CHADS2 Score ≥2 Age ≥18 Patient inform orally write Written informed consent patient Patients anticipate show sufficient compliance follow study protocol Patients must agree undergo 148 day clinical followup Patients mentally linguistically able understand aim study associate risk benefit treatment . The patient , provide informed consent , agree treatment state patient inform consent document . Strong clinical evidence prevents temporary pause therapy AT II antagonists Symptomatic bradycardia Implanted pacemaker implant cardioverter/defibrillator antitachycardia algorithm use Cardiac surgery cardiac catheter ablation within last 3 month prior randomisation Typical angina pectoris symptom rest exercise Known coronary artery disease indication intervention Symptomatic peripheral vascular disease Left ventricular ejection fraction &lt; 35 % Myocardial infarction within 6 month prior randomisation Diastolic blood pressure &gt; 110mmHg rest Symptomatic arterial hypotension Known renal artery stenosis Serum creatinin &gt; 1.8mval/l Chronic inflammatory disease Acute inflammatory disease ( CRP &gt; 20mg/L ) Relevant hepatic pulmonary disorder Hyperthyreosis manifest clinically laboratory Known drug intolerance AT II inhibitor Females pregnant breast feeding Females childbearing potential use scientifically accept method contraception Participation clinical trial within last 30 day prior randomisation Drug addiction chronic alcohol abuse Cancer disease , inevitably lead death Legal incapacity , circumstance would prevent patient understanding aim , nature extent clinical study , evidence uncooperative attitude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>irbesartan</keyword>
	<keyword>AT-II-antagonist</keyword>
	<keyword>Adhesion Molecules</keyword>
	<keyword>oxidative stress marker</keyword>
	<keyword>hsCRP</keyword>
	<keyword>ICAM</keyword>
	<keyword>VCAM</keyword>
	<keyword>MCP-1</keyword>
	<keyword>vWF</keyword>
	<keyword>TGFβ1</keyword>
	<keyword>TNF-α</keyword>
	<keyword>Interleukin-6</keyword>
	<keyword>8isoProstaglandinF2α</keyword>
</DOC>